Key facts
- Dia Beta Labs’s last known valuation is $2.6M (Dec 2024).
- It has raised $2.4M; the latest was Early Stage VC ($1.6M) in Aug 2025.
- Notable investors include Innovate UK, UK Research and Innovation, Clarendon Fund Managers, DSW Ventures, Duncreggan Student Village — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Dia Beta Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Dia Beta Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dia Beta Labs
Operator of a biotechnology company committed to transforming the lives of metabolic disease sufferers. The company is developing agents to address the progressive decline of pancreatic health in sufferers while imparting more sustainable, quality weight loss than currently available options, enabling diabetic patients with insulin-producing beta-cells.
- Sector
- Healthcare
- HQ
- Belfast, United Kingdom
- Founded
- 2022
- Employees
- 5
- Website
- diabetalabs.com/
- Ownership
- Privately Held (backing)
Dia Beta Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dia Beta Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dia Beta Labs in its N-PORT filings yet. We sweep new filings monthly.